Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + adebrelimab + lenvatinib for conversion treatment in potentially resectable locally advanced biliary tract cancer
ChiCTR2400083336Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and lenvatinib in biliary cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: R0 resection rate and Surgery conversion rate. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimablenvatinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400083336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083336.